Financhill
Back

Lyell Immunopharma Quote, Financials, Valuation and Earnings

Lyell Immunopharma Price Quote

$2.36

Lyell Immunopharma Key Stats

Sell
49
Lyell Immunopharma (LYEL) is a Sell

Day range:
$2.35 - $2.66
52-week range:
$1.32 - $3.97
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
4,556.23
P/B ratio:
0.92%

Volume:
446K
Avg. volume:
850.4K
1-year change:
1.72%
Market cap:
$599.7M
Revenue:
$130K
EPS:
$-0.93

How Much Does Lyell Immunopharma Make?

Is Lyell Immunopharma Growing As A Company?

  • What Is Lyell Immunopharma's Growth Rate Quarterly?
    Quarterly YoY revenue growth is -1%
  • What Is Lyell Immunopharma's EPS Quarterly YoY Growth Rate?
    Quarterly, year-over-year diluted EPS growth rate is 0%

Lyell Immunopharma Stock Price Performance

What Is Lyell Immunopharma 52-Week High & Low?

Lyell Immunopharma Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Lyell Immunopharma?

Is Lyell Immunopharma Cash Flow Positive?

  • What Is LYEL Cash Flow From Operations?
    Cash flow from operations (TTM) is -$163.7M
  • What Is Lyell Immunopharma’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $1.7M
  • What Is Lyell Immunopharma’s Cash Flow From Investing?
    Cash flow from investing (TTM) is $184M

Lyell Immunopharma Return On Invested Capital

  • Is Management Doing A Good Job?
    LYEL return on invested capital is -31.65%
  • What Is Lyell Immunopharma Return On Assets?
    ROA measures how assets are converting to revenues and is -27.94%
  • What Is LYEL Return On Equity?
    ROE is a measure of profitability and is -31.65%

Lyell Immunopharma Earnings Date & Stock Price

Lyell Immunopharma Competitors

  • Who Are Lyell Immunopharma's Competitors?
    Below is a list of companies who compete with Lyell Immunopharma or are related in some way:
    • Candel Therapeutics Inc (CADL)
    • Eliem Therapeutics Inc (ELYM)
    • GlycoMimetics Inc (GLYC)
    • NovaBay Pharmaceuticals Inc (NBY)
    • Entrada Therapeutics Inc (TRDA)

Lyell Immunopharma Dividend Yield

Data Unavailable

Lyell Immunopharma Analyst Estimates

YoY Growth Past Surprise
EPS: 0% 15.27%
Revenue: -99.97% 0%

Analyst Recommendations

Buy Recommendations: 1
Hold Recommendations: 2
Sell Recommendations: 0
Price Target: 6.33
Upside from Last Price: 168.36%

Major Shareholders

  • How many LYEL shares are owned by institutional investors?
    161.9M LYEL shares are owned by institutional investors
  • How many LYEL shares are owned by insiders?
    8.1M LYEL shares are owned by insiders